NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 119 filers reported holding NURIX THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,381,349 | -9.8% | 2,593,047 | +14.7% | 0.16% | +4.0% |
| Q2 2023 | $22,588,099 | +13.6% | 2,261,071 | +0.9% | 0.15% | +9.5% |
| Q1 2023 | $19,889,948 | -8.9% | 2,239,859 | +12.7% | 0.14% | -27.5% |
| Q4 2022 | $21,831,029 | +30.2% | 1,988,254 | +54.5% | 0.19% | +61.5% |
| Q3 2022 | $16,763,000 | +113.4% | 1,286,522 | +65.2% | 0.12% | +154.3% |
| Q2 2022 | $7,857,000 | +43.1% | 778,725 | +98.7% | 0.05% | +100.0% |
| Q1 2022 | $5,492,000 | +331.8% | 391,991 | +792.0% | 0.02% | +475.0% |
| Q4 2021 | $1,272,000 | – | 43,947 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |